

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

05 FEB 11 AM

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Wheat Government Relations			
2. Address <input type="checkbox"/> Check if different than previously reported 1201 South Eads Street Suite Two			
3. Principal Place of Business (if different from line 2) City: Arlington State/Zip (or Country) VA 22202			
4. Contact Name Alan Wheat	Telephone (703) 271-8770	E-mail (optional) awheat@wheatgr.com	5. Senate ID # 4719
7. Client Name <input type="checkbox"/> Self GlaxoSmithKline			6. House ID # 3438

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) ☐ OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ → Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>\$40,000.00</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6011 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code</p>
---	--

Signature

Printed Name and Title

Alan Wheat, President

Registrant Name Wheat Government Relations Client Name GlaxoSmithKline

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

H.R. 5006 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2005
S. 2810 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2005
H.R. 4818 Consolidated Appropriations Act, 2005
Drug Importation
AIDS Drug Assistance Programs


17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Alan Wheat	
Julie Shroyer	
Steve Dye	
MaryAnne Sapio	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date _____
Printed Name and Title Alan Wheat, President

Registrant Name Wheat Government Relations Client Name GlaxoSmithKline

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R.4923/S.2493 Safe IMPORT Act of 2004
H.R.4790 Drug Importation Promotion and Safety Act
S.2328 Pharmaceutical Market Access and Drug Safety Act of 2004
H.R. 2929 New Aid for Trustworthy, Affordable Drugs Act (NAFTA Drugs Act)

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Alan Wheat	
Julie Shroyer	
Steve Dye	
MaryAnne Sapio	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date _____

Printed Name and Title Alan Wheat, President

